Dr @ljlaffin presents the results of the #SPORT trial. Rosuva 5mg/d lowered LDL significantly more than 6 dietary supplements commonly used for cholesterol health. In fact no supplement lowered LDL-C more that placebo and garlic supplement actually raised LDL. #AHA22@AHAScience
Notably in this short term trial, no increase in musculoskeletal or neurological symptoms or worsening glycemia with rosuva 5. All participants with rosuva 5 had LDL lowering (coin toss for supplements), 50% had LDL>40% reduced with rosuva 5. #AHA22
77% of US adults take supplements and $50 billion is spent annually in US on supplements. But do they lower LDL? These supplements advertise that they help heart health but no better in lowering LDL than placebo not even red yeast rice. @ljlaffin#AHA22@AHAScience
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Now up, growing your program through modern media by @purviparwani. In current era, #SoMe is a powerful tool for growing your program. #SCCT2021
Strategies for growing your growing your advanced imaging program through modern media. Great talk by @purviparwani#SCCT2021
5 tips for growing #CardiacCT program @purviparwani#SCCT2021. Tip 1: Make imaging relevant to clinical problem. Tip 2: Imaging content on #SoMe. Tip 3: 80/20 rule of original content/promotion. Tip 4: 360 degree Marketing
#YesCCT : Clinical reporting & understanding finance by @docjuanb at #SCCT2021 . There are reimbursement challenges . #Cardiac CT is in the wrong Ambulatory Payment Classification (APC). Bill also must be supported by clinical symptom & diagnostic ICD10 codes. Not a “rule out”.
Reimbursement tracks with the CPT used so use the right CPT code and make sure language in report supports that code. All CTA assumes 3D, thus need to mention 3D in report. Have your reporting align with @Heart_SCCT guidelines. @docjuanb at #SCCT2021
Unfortunately #cardiacCT often lumped into CT not cardiac. Hospitals should update cost charges to accurately reflect true cost of work, align w/ other cardiac testing. With costs underreported, CMS bases APC & reimbursement on these historically lower costs @docjuanb#SCCT2021
Obstructive CAD is just one etiology of ischemia. If no obstructive disease, consider coronary microvascular dysfunction #CMD. So what is best imaging modality for CMD? @VTaqMD#SCCT2021
How to evaluate for #CMD? A multidimensional cardiac stress PET test can evaluation for perfusion, function, and coronary blood flow. @VTaqMD#SCCT2021
Distribution of risk by coronary flow reserve #CFR. Even in absence of inducible ischemia or obstructive lesions, impaired CFR is associated with increased CVD risk. When severely impaired, CFR more prognostically significant in women. @VTaqMD#SCCT2021
Patients with #MINOCA were more likely to be women and have fewer traditional CV risk factors. Heterogenous pathophysiology – etiology is of great importance to guide treatment. Inge van den Hoogen #SCCT2021
#MINOCA diagnosis. Overt non-cardiac disorders need to be excluded. Also need to rule out missed obstruction and non-ischemic causes of myocardial injury. Then after MINOCA diagnosed, need to workup etiology. Inge van den Hoogen #SCCT2021
Plaque disruption and plaque erosion cause some cases of #MINOCA – diagnose with OCT or IVUS, but not CCTA. Inge van den Hoogen #SCCT2021
Women are not smaller men! #Atherosclerosis genesis, progression & sequelae different in women. Plaque erosion causing ACS more common in women. Women have unique #SDOH, are undertreated with #cvPrev therapies & #GDMT, leads to worsening outcomes in women. @lesleejshaw#SCCT2021
Women’s CVD risk can be underestimated. Female specific risk enhancers help. #CAC if risk uncertain. Women have lower #CAC prevalence than men but prevalence increases after menopause. CAC when present confers greater risk of incident CVD in women than men. @lesleejshaw#SCCT2021
Prevalence of non-obstructive #CAD is higher in women but is prognostic of risk. @lesleejshaw#SCCT2021